Recently Added |View All
News
Dr. Mark Farrugia describes new approach to post-operative radiation therapy for non-small cell lung cancer
News
Drug application in review based on trial co-led by Roswell Park’s Dr. Eunice Wang in patients with NPM1-mutant AML.
News
Phase 1 Clinical Trial Offers FDA Fast-Tracked Drug for Relapsed/Refractory AML and MDS
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center offers a promising treatment option for patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Video
Clinical CAR T-cell Trial for Multiple Myeloma Suggests Possible “Cure”
For the first time, patients on a new CAR T-cell therapy for multiple myeloma are experiencing remission long enough to be cautious deemed cured of their disease.
News
Research Leaders Across New York State Form Empire State Cellular Therapy Consortium
To expand on early progress in the emerging field of cell and gene therapy, five research centers across New York State are collaborating to develop new cell therapies for cancer and other diseases.
News
Patients with metastatic, castration-resistant prostate cancer (mCRPC) have a median overall survival of only about two to three years, but genomic sequencing is making inroads against that grim prognosis.
Video
Cellular Therapies Leading to New Treatment Options for Lymphoma Patients
A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.
Video
New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients
Roswell Park Comprehensive Cancer Center offers gynecologic cancer patients multidisciplinary care from nationally recognized specialists who collaborate on personalized treatment plans.
News
Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM
Roswell Park Comprehensive Cancer Center announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED